Table 3.
FARPRESTO multilevel assessment
| Assessments | Mandatory | Inclusion | Follow-up | |
|---|---|---|---|---|
| Sociodemographic | Date and place of birth | X | X | |
| Social security number | X | X | ||
| Sex | X | X | ||
| Marital status | X | X | ||
| Years of education | X | |||
| Employment | X | |||
| Preliminary information | Medical history | X | X | X |
| Current therapy | X | X | X | |
| Tobacco use | X | X | X | |
| Alcohol use | X | X | X | |
| Toxic substances exposure | X | X | X | |
| Family history | X | X | X | |
| Physical activity | X | X | X | |
| RBD related injuries | X | X | ||
| Dream content | X | X | X | |
| Minimum set of diagnostic tests | RBD diagnosis (ICSD-2, ICSD-3) | X | X | |
| UPDRS III/MDSUPDRS III | X | X | X | |
| MMSE/MoCA | X | X | X | |
| Neuroimaging (MRI/CT) | X | X | ||
| Disease outcomes | Phenoconversion | X | ||
| Death | X | |||
| I level | RBD onset | X | ||
| PSG edf | X | |||
| RSWA quantification | X | |||
| Hyposmia | X | X | ||
| Constipation | X | X | ||
| Urgency-urinary dysfunction | X | X | ||
| Erectile dysfunction | X | X | ||
| Orthostatic hypotension | X | X | ||
| Depression | X | X | ||
| Hallucinations | X | X | X | |
| EQ5D | X | X | ||
| PSQI | X | X | ||
| II level | Neuropsychological evaluation | X | X | |
| Spect DAT scan | X | X | ||
| III level | Skin biopsy | X | X | |
| Salivary alpha-synuclein | X | X | ||
| Pupillometry | X | X | ||
| OCT | X | X | ||
| Genetic | X | X |
(MDS)UPDRS-III, (Movement Disorders Society) Unified Parkinson’s Disease Rating Scale Part III; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; MRI, magnetic resonance imaging; CT, computed tomography; PSG edf, polisomnography European Data Format file; RSWA, REM sleep without atonia; EQ5D, EuroQol Group’s quality of life questionnaire; PSQI, Pittsburg sleep quality index; OCT, optical coherence tomography